SAN DIEGO, March 29 (Bernama-GLOBE NEWSWIRE) — Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation and autoimmune, cardiovascular and metabolic disease research announced today that parent company, JSR Corporation, has entered into a strategic partnership with Hubrecht Organoid Technology (HUB).
The agreement provides CrownBio, a wholly owned subsidiary of JSR Corporation, with an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, including access to HUB’s highly characterized tumor organoid biobank. CrownBio and HUB will also launch a collaborative research & development program to accelerate further development of Organoid Technology, while CrownBio will establish a new operations center in Utrecht, Netherlands.